Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Administration of Gemcitabine Plus Doxorubicin Followed by Gemcitabine Plus Cisplatin in Large or Locally Advanced Operable Breast Cancer: A Phase II Study

NCT00191789 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00191789
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00191789 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Administration of Gemcitabine Plus Doxorubicin Followed by Gemcitabine Plus Cisplatin in Large or Locally Advanced Operable Breast Cancer: A Phase II Study
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2003
Completion date
April 30, 2009
Enrollment
65 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer